SCHEMBL6478489

SCHEMBL6478489

Cc1cccc(C(=O)N(C(=O)c2cccc(C)c2)c2nc3ccccc3c(NCc3ccccc3)c2C#N)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MAPT P10636 4/20 0.45
CYP1A2 P05177 3/20 0.45
CYP2D6 P10635 3/20 0.45
CYP2C19 P33261 3/20 0.45
TSHR P16473 3/20 0.45
ALOX15 P16050 2/20 0.45
HIF1A Q16665 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 2/20 0.45
KMT2A Q03164 5/20 0.44
VNN1 O95497 2/20 0.44
POLB P06746 2/20 0.44
RAD52 P43351 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
GRM1 Q13255 1/20 0.43
NPSR1 Q6W5P4 3/20 0.40
APP P05067 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5220504 0.89 KMT2A (0.48) LMNACYP1A2CYP2D6CYP2C19TSHR
SCHEMBL5224357 0.83 KMT2A (0.47) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL5460979 0.83 ADORA3 (0.46) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL6480798 0.83 ALDH1A1 (0.48) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL6489855 0.82 ADORA3 (0.49) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL6491520 0.79 KMT2A (0.46) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL5224004 0.74 ADORA3 (0.42) LMNAMAPTCYP1A2CYP2D6CYP2C19
SCHEMBL941232 0.74 SMN1; SMN2 (0.42) LMNAMAPTCYP2C19TSHRHPGD
SCHEMBL5462040 0.74 ADORA3 (0.42) LMNAMAPTCYP1A2CYP2C19TSHR
SCHEMBL5224155 0.74 KMT2A (0.45) LMNAMAPTCYP1A2CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP disclosed
US-6969723-B2 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI - AVENTIS (FR) 2005-11-29 US disclosed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US disclosed
EP-1390349-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2004-02-25 EP disclosed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO disclosed
WO-2002096879-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-SYNTHELABO (FR) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands ADORA3, ADORA1, ADORA2A LMNA 2918/4885MAPT 4760/4885CYP1A2 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.